# GH Research PLC (GHRS) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $28.23, market value $1.9 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). GH Research PLC reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 5.4×**. The shares trade at 5.4× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -2.7%** (5-yr avg -7.0%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -17.3%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): -5.3%**. Earnings per share fell 5.3%.

## Financial health
- **Debt to equity: 0.00**. Debt is 0.00 times equity: a conservative balance sheet.

## Dividends
- **Dividend: none**. GH Research PLC does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 100.9%** (YTD 122.3%, 3-mo 31.7%). The shares are up 100.9% over twelve months including dividends.
- **From 52-week high: -10.2%** (138.6% above the low). Trading 10% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 50**. An RSI of 50 is neutral.
- **Beta (1 yr): 1.48** (volatility 73%). Beta of 1.48 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=GHRS · Page: https://foliofundamentals.com/stocks/ghrs

Not investment advice.